uPA and PAI-1 in Rectal Cancer-Relationship to Radiotherapy and Clinical Outcome

Journal of Surgical Research

Volumn 153, Issue 1, 2009, Pages 46-53

  Angenete, Eva ^a   Langenskiöld, Marcus ^a   Palmgren, Ingrid ^a   Falk, Peter ^a   Öresland, Tom ^b   Ivarsson, Marie Louise ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c Kungsbacka Hospital   (Sweden)

Author keywords

metastases; PAI 1; radiotherapy; rectal cancer; uPA

Indexed keywords

ANTIBIOTIC AGENT; FLUOROURACIL; FOLINIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECTUM BIOPSY; RECTUM CANCER; RECURRENT DISEASE; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; RECTUM; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 63649152323     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.02.043     Document Type: Article

References (35)

1. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638
2. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 (1997) 980
3. Folkesson J., Birgisson H., Pahlman L., et al. Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23 (2005) 5644
4. Dahlberg M., Glimelius B., Graf W., et al. Preoperative irradiation affects functional results after surgery for rectal cancer: Results from a randomized study. Dis Colon Rectum 41 (1998) 543 discussion 549
5. Birgisson H., Pahlman L., Gunnarsson U., et al. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol 46 (2007) 504
6. Brown G., Davies S., Williams G.T., et al. Effectiveness of preoperative staging in rectal cancer: Digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. Br J Cancer 91 (2004) 23
7. Smith N.J., Bees N., Barbachano Y., et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: Implications for clinical trials. Br J Cancer 96 (2007) 1030
8. Jass J.R., O'Brien M.J., Riddell R.H., et al. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol 38 (2007) 537
9. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313
10. Duffy M.J., van Dalen A., Haglund C., et al. Tumor markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Eur J Cancer 43 (2007) 1348
11. Angenete E., Langenskiold M., Falk P., et al. Matrix metalloproteinases in rectal mucosa, tumor and plasma: Response after preoperative irradiation. Int J Colorectal Dis 22 (2007) 667
12. Angenete E., Langenskiold M., Palmgren I., et al. Transforming growth factor beta-1 in rectal tumor, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Int J Colorectal Dis 22 (2007) 1331
13. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57 (2000) 25
14. Berger D.H. Plasmin/plasminogen system in colorectal cancer. World J Surg 26 (2002) 767
15. Yang J.L., Seetoo D., Wang Y., et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 89 (2000) 431
16. Ganesh S., Sier C.F., Griffioen G., et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54 (1994) 4065
17. Mulcahy H.E., Duffy M.J., Gibbons D., et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344 (1994) 583
18. Bajou K., Masson V., Gerard R.D., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152 (2001) 777
19. Dellas C., and Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93 (2005) 631
20. Gunther K., Dworak O., Remke S., et al. Prediction of distant metastases after curative surgery for rectal cancer. J Surg Res 103 (2002) 68
21. Abe J., Urano T., Konno H., et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 86 (1999) 2602
22. Sakakibara T., Hibi K., Koike M., et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 93 (2005) 799
23. Nielsen H.J., Christensen I.J., Sorensen S., et al. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 7 (2000) 617
24. Nielsen H.J., Pappot H., Christensen I.J., et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 316 (1998) 829
25. Harbeck N., Kates R.E., Look M.P., et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62 (2002) 4617
26. Harbeck N., Thomssen C., Berger U., et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 54 (1999) 147
27. Lowry O., Rosebrough N.J., Farr A.L., et al. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265
28. Richter K.K., Fink L.M., Hughes B.M., et al. Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum. Am J Surg 176 (1998) 642
29. Baker E.A., and Leaper D.J. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: Relationship to tumor pathology. Eur J Cancer 39 (2003) 981
30. Baker E.A., Bergin F.G., and Leaper D.J. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 53 (2000) 307
31. Strup-Perrot C., Vozenin-Brotons M.C., Vandamme M., et al. Expression and activation of MMP -2, -3, -9, -14 are induced in rat colon after abdominal X-irradiation. Scand J Gastroenterol 41 (2006) 60
32. Zhao W., Spitz D.R., Oberley L.W., et al. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res 61 (2001) 5537
33. Hageman J., Eggen B.J., Rozema T., et al. Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene. Clin Cancer Res 11 (2005) 5956
34. Marijnen C.A., Nagtegaal I.D., Kapiteijn E., et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 1311
35. Bajou K., Noel A., Gerard R.D., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4 (1998) 923